Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

280 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
The spectrum of neuromyelitis optica.
Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. Wingerchuk DM, et al. Among authors: weinshenker bg. Lancet Neurol. 2007 Sep;6(9):805-15. doi: 10.1016/S1474-4422(07)70216-8. Lancet Neurol. 2007. PMID: 17706564 Review.
A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica.
Lucchinetti CF, Mandler RN, McGavern D, Bruck W, Gleich G, Ransohoff RM, Trebst C, Weinshenker B, Wingerchuk D, Parisi JE, Lassmann H. Lucchinetti CF, et al. Among authors: weinshenker b. Brain. 2002 Jul;125(Pt 7):1450-61. doi: 10.1093/brain/awf151. Brain. 2002. PMID: 12076996 Free PMC article.
Neuromyelitis optica: clinical predictors of a relapsing course and survival.
Wingerchuk DM, Weinshenker BG. Wingerchuk DM, et al. Among authors: weinshenker bg. Neurology. 2003 Mar 11;60(5):848-53. doi: 10.1212/01.wnl.0000049912.02954.2c. Neurology. 2003. PMID: 12629245
Neuromyelitis optica: what it is and what it might be.
Weinshenker BG. Weinshenker BG. Lancet. 2003 Mar 15;361(9361):889-90. doi: 10.1016/S0140-6736(03)12784-5. Lancet. 2003. PMID: 12648964 No abstract available.
Bright red nuclei.
Pittock SJ, Weinshenker BG, Lucchinetti CF. Pittock SJ, et al. Among authors: weinshenker bg. Neurology. 2004 Feb 24;62(4):619. doi: 10.1212/01.wnl.0000116137.67886.f8. Neurology. 2004. PMID: 14981180 No abstract available.
Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn's disease.
Thomas CW Jr, Weinshenker BG, Sandborn WJ. Thomas CW Jr, et al. Among authors: weinshenker bg. Inflamm Bowel Dis. 2004 Jan;10(1):28-31. doi: 10.1097/00054725-200401000-00004. Inflamm Bowel Dis. 2004. PMID: 15058523
Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study.
Pittock SJ, McClelland RL, Mayr WT, Jorgensen NW, Weinshenker BG, Noseworthy J, Rodriguez M. Pittock SJ, et al. Among authors: weinshenker bg. Ann Neurol. 2004 Aug;56(2):303-6. doi: 10.1002/ana.20197. Ann Neurol. 2004. PMID: 15293286
The natural history of recurrent optic neuritis.
Pirko I, Blauwet LA, Lesnick TG, Weinshenker BG. Pirko I, et al. Among authors: weinshenker bg. Arch Neurol. 2004 Sep;61(9):1401-5. doi: 10.1001/archneur.61.9.1401. Arch Neurol. 2004. PMID: 15364686
Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.
Panitch H, Miller A, Paty D, Weinshenker B; North American Study Group on Interferon beta-1b in Secondary Progressive MS. Panitch H, et al. Among authors: weinshenker b. Neurology. 2004 Nov 23;63(10):1788-95. doi: 10.1212/01.wnl.0000146958.77317.3e. Neurology. 2004. PMID: 15557491 Clinical Trial.
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis.
Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, Nakashima I, Weinshenker BG. Lennon VA, et al. Among authors: weinshenker bg. Lancet. 2004 Dec 11-17;364(9451):2106-12. doi: 10.1016/S0140-6736(04)17551-X. Lancet. 2004. PMID: 15589308
280 results
Jump to page
Feedback